Abstract Purpose: Cell cycle dysregulation resulting in expression of antiapoptotic genes and uncontrolled proliferation is a feature of undifferentiated nasopharyngeal carcinoma. The pharmacodynamic effects of seliciclib, a cyclin-dependent kinase (CDK) inhibitor, were studied in patients with nasopharyngeal carcinoma. Experimental Design: Patients with treatment-naI« ve locally advanced nasopharyngeal carcinoma received seliciclib at 800 mg or 400 mg twice daily on days 1 to 3 and 8 to 12. Paired tumor samples obtained at baseline and on day 13 were assessed by light microscopy, immunohistochemistry, and transcriptional profiling using real-time PCR low-density array consisting of a panel of 380 genes related to cell cycle inhibition, apoptosis, signal transduction, and cell proliferation. Results: At 800 mg bd, one patient experienced grade 3 liver toxicity and another had grade 2 vomiting; no significant toxicities were experienced in 13 patients treated at 400 mg bd. Seven of fourteen evaluable patients had clinical evidence of tumor reduction. Some of these responses were associated with increased tumor apoptosis, necrosis, and decreases in plasma EBV DNA posttreatment. Reduced protein expression of Mcl-1, cyclin D1, phosphorylated retinoblastoma protein pRB (T821), and significant transcriptional down-regulation of genes related to cellular proliferation and survival were shown in some patients posttreatment, indicative of cell cycle modulation by seliciclib, more specifically inhibition of cdk2/cyclin E, cdk7/cyclin H, and cdk9/cyclinT. Conclusions: Brief treatment with this regimen of seliciclib in patients with nasopharyngeal carcinoma is tolerable at 400 mg bd and associated with tumor pharmacodynamic changes consistent with cdk inhibition, and warrants further efficacy studies in this tumor.
A common feature of cancer is dysregulated cell cycle control that allows uncontrolled cell cycle progression through events that promote global gene transcription (1) . These defects could be a result of activation of cyclin-dependent kinases (cdk) 4 and 6 or their regulatory D-type cyclins, loss of function of cdk inhibitors like p16 INK4A , p27 kip1 , loss of activity of p53, or excessive activity of cdk4/6. Whereas cdk4 and 6 and cdk2 when associated with their cyclins are known to activate S-phase DNA replication through retinoblastoma protein phosphorylation and consequent unbridled transcriptional effects of E2F, CDK7/9 are able to maintain gene transcription by activating RNA polymerase II (1 -3) . It is known that cancer cells require continuous expression of antiapoptotic genes for maintenance of their transformed state (4) . Therefore, downregulation of gene transcription through inhibition of CDK2, CDK7/9 would result in apoptosis. Cell cycle inhibitors exploit this mechanism as potential anticancer drugs.
Seliciclib (Cyclacel Ltd.; CYC202; R-roscovitine), an orally administered small molecule inhibitor of the serine/threonine kinases CDKs, through competition with ATP for binding, can induce apoptosis in several human tumor cell lines, including nasopharyngeal carcinoma, through inhibition of retinoblastoma and RNA polymerase II carboxy terminal domain phosphorylation, leading to a reduction in levels of key antiapoptotic proteins like Mcl-1 and XIAP, and cell cycle regulators such as cyclin D1 (5 -7) . The IC 50 of seliciclib for the various cdks are in similar ranges [cdk2/cyclin E (0.1 Amol/L), cdk7/cyclin H (0.36 Amol/L), and cdk9/cyclin T (0.8 Amol/L); ref. 8] . Seliciclib is currently in phase II clinical trials in combination with chemotherapy in breast and non -small cell lung cancer, but its pharmacodynamic effects of cdk inhibition by itself in solid tumors in vivo have not been shown. In chronic lymphocytic leukemia cells in vitro, seliciclib has been shown to induce apoptosis through the down-regulation of genes, and a similar mechanism of apoptosis has been described with another cdk inhibitor flavopiridol (9) .
Undifferentiated nasopharyngeal cancer is an aggressive disease common in SouthEast Asia, and although concurrent chemoradiotherapy has improved the outcome of locally advanced disease, toxicities associated with definitive treatment and the poor outcome of recurrent disease with chemotherapy necessitate the development of more effective and less toxic alternatives. Cell cycle dysregulation is frequently found in nasopharyngeal carcinoma, in which activating cyclins such as cyclin D1 are often overexpressed whereas cyclin-dependent kinase inhibitors such as p16 INK4A are down-regulated (10 -12) . This promotes association between cyclin D1 with cdks 4 and 6 to facilitate G 1 progression through phosphorylation of retinoblastoma, thereby promoting E2F-mediated gene transcription (1) . These cell cycle defects have significance for treatment, as restoration of p16 expression or inhibition of cyclin D1 by small interfering RNA reduces proliferation of nasopharyngeal carcinoma cell lines (13) .
On this basis, we conducted a clinical study of seliciclib in patients with untreated nasopharyngeal carcinoma to determine its tolerability, pharmacokinetics, and clinical as well as cellular effects.
Patients and Methods
Patients with treatment-naBve, localized, histologically confirmed WHO type III undifferentiated nasopharyngeal carcinoma were enrolled. Other eligibility criteria included age z21 y, Eastern Cooperative Oncology Group performance status of 0 or 1, and adequate bone marrow, renal, and hepatic function. Patients were excluded if they were on alternative medications, had uncontrolled major medical conditions, were pregnant or lactating, had evidence of malabsorption, had other malignancies within 5 y, or were known carriers of hepatitis B or C or HIV. The protocol was approved by the local institutional review board and all patients gave written informed consent prior to participation.
Treatment, procedures, and methodology. Baseline history, physical examination, performance status, biochemical profile, and complete blood count were done within 7 d before starting treatment. Patients had endoscopic assessment of tumor with tumor biopsy within 72 h prior to commencing seliciclib and on day 13 of treatment. Seliciclib was supplied by Cyclacel Ltd in 200-mg capsules. Previous phase I studies have established that 800 mg/m 2 twice daily for 7 d is associated with dose-limiting toxicities; 5 d continuous dosing seemed to be tolerable (14) . Therefore, patients were orally administered a starting dose of 800 mg bd at least 2 h postprandial on days 1 to 3 and 8 to 12 for a single 14-day cycle. Treatment of three patients was planned at this dose level 1 with an additional three patients to be treated if one patient had dose-limiting toxicities. Further enrollment at level 1 would continue if no more than two of six patients had dose-limiting toxicities. Reduction to dose level 2 was mandated if more than one of the first three patients exhibited dose-limiting toxicities. Patients were seen on days 8 and 12 for repeat laboratory testing, assessment of treatment compliance, and toxicity according to National Cancer Institute Common Toxicity Criteria version 2.
Tumor measurements and assessments. Bidimensional tumor measurements were done on all palpable cervical lymph nodes at pretreatment and on days 8 and 12 using skin calipers. The sum of the products of the pretreatment measurements was subtracted from the sum of the product of the posttreatment measurements and divided by the sum of the product of the pretreatment measurements. Patients with >25% decrease in the sum of the product of the posttreatment measurements were considered to show clinical response. Computed tomography scans of the nasopharynx and neck were done within 2 wk of starting seliciclib and immediately following treatment with seliciclib for radiotherapy planning, and tumor measurements were made according to the Response Evaluation Criteria In Solid Tumors.
Immunohistochemistry and histologic examination. Tumor tissue was assessed for the following biomarkers: cyclin D1, Mcl-1, phosphorylated retinoblastoma-Ser807/811 (cdk4-specific phosphorylation site) and pT821 (cdk2-specific phosphorylation site), Ki67 expression, and apoptosis (terminal deoxynucleotidyl transferase biotin-dUTP nick end Labeling or TUNEL staining). Light microscopy was used to evaluate histologic changes using H&E staining.
After deparaffinization and rehydration, antigen retrieval was done by boiling in citrate buffer in a pressure cooker (Milestone, T/T Mega). Endogenous peroxidase activity was blocked with incubation in 0.03% hydrogen peroxide/sodium azide buffer for 5 min. Primary antibody was then applied at appropriate dilution overnight at room temperature The pretreatment and posttreatment samples were assessed for extent and intensity of staining using a semiquantitative score of 0 to
Translational Relevance
Cell cycle inhibitors have not been shown previously to induce molecular changes in vivo in solid cancers. Using a window design clinical study, we showed that seliciclib down-regulated transcription of genes relevant to EBVmediated tumorigenesis and control of apoptosis through activation of signaling pathways that included mitogenactivated protein kinase, c-Jun NH 2 -terminal kinase, p38, Janus kinase/signal transducer and activator of transcription, nuclear factor nB, phosphoinositide 3-kinase/protein kinase B, and RhoGTPases in nasopharyngeal cancer, where EBV-mediated transformation and expression of latent membrane protein 1 has been associated with carcinogenicity. In addition, nasopharyngeal carcinoma is characterized by dysregulation of the cell cycle, particularly through overexpression of cyclin D1 and silencing of p16 INK4A , promoting gene transcription. Therefore, inhibition of these pathways potentially restores cell cycle regulatory events. This proof of principle provides the evidence required for a formal evaluation of cell cycle inhibitors in nasopharyngeal cancer, and represents a significant advance in the application of novel moleculartargeted agents to therapy of this cancer.
3, and then compared and reported as increased expression, decreased expression, or maintenance of the expression. Only those cases with a clear, unequivocal difference leading to up-or downregulation were scored as such, to avoid possible false positives in borderline cases. Scoring was done by two independent pathologists who were blinded to the timing of sample collections. After examination of all the collected paired pretreatment and posttreatment samples, only those in which it was perceived that the biopsy was deep enough to represent tumor primarily (as opposed to adjacent surface epithelium) were considered suitable.
Low-density array real-time reverse transcriptase-PCR. Total RNA from snap-frozen tumor samples was extracted using Tri-Reagent (Molecular Research Centre Inc.). Total RNA yields and purity were determined using the ND-100 Spectrophotometer (Nanodrop Technologies). Public databases and publications were extensively reviewed to identify 380 genes involved in pathways of cell proliferation, cell cycle regulation, and apoptosis. Real-time reverse transcription-PCR analysis was carried out using the Micro-Fluidic Cards system (Applied Biosystems), preloaded with inventoried TaqMan Gene Expression Assays for the selected genes according to the manufacturer's instructions. Briefly, 1.2 Ag of total RNA was reverse transcribed into cDNA using the cDNA Reverse Transcription Kit (Applied Biosystems). Ten microliters of cDNA sample were mixed with 490 AL of nucleasefree water and 500 AL of 2 Â PCR master mix. One hundred microliters of the reaction mix were loaded into each of the eight sample ports on the Micro-Fluidic Cards. Thereafter, the cards was centrifuged twice for 1 min at 331 Â g at room temperature and then sealed and analyzed on the ABI PRISM 7900 HT Sequence Detection System (Applied Biosystems). Relative gene expression levels were determined by SDS 2.2.1 software using the DCt method (Applied Biosystems). Expression levels of target genes were normalized to GAPDH.
Plasma EBV viral copies. DNA from plasma samples obtained at baseline and on day 12 of seliciclib treatment was extracted using QIAamp Blood Kit (Qiagen). Plasma EBV DNA copy number, a specific validated marker of clinical tumor burden and treatment response in nasopharyngeal carcinoma (15, 16) , was quantitated using real-time PCR primers and the probe targeted the BamHI-W region of the EBV genome as previously described (17) .
Pharmacokinetic analysis. Pharmacokinetic samples were drawn from all patients at 0, 1, 2, 4, and 6 h on days 1 and 12 of treatment. Plasma levels of seliciclib and its most abundant carboxylated metabolite, PEF30-128, were assayed using a validated liquid chromatography-tandem mass spectrometry method at ACC, Germany. Noncompartmental pharmacokinetic analysis based on the individual patient's area under the concentration-time curves (AUCs) was done using the log-linear trapezoidal option, from time 0 to the last time point of each sampling period as well as from time 0 to infinity. Pharmacokinetic analyses were carried out using Kinetica version 4.4 (Innaphase Corp.).
Statistical analysis. Changes in gene expression for the panel of genes for each patient in the dataset were subjected to unsupervised hierarchical clustering to cluster patients with common gene expression changes. For each gene G, the ''relative expression value'' e G between day0 and day13 as e G = day13/day0 if day13 >day0, and as e G = -day0/ day13 if day0 >day13. Hence eG = 3 means its day13 value is 3 times its day0 value, and eG = -3 means its day13 value is only 1/3 of its day0 value. Only genes that satisfied all of the following: (a) have present calls in >80% of samples, (b) SD > 0, (c) at least one observation has |e G | > 2, and (d) the maximum and minimum values differ by at least 2, were retained. Of the 384 genes, only 283 met these conditions. Two-dimensional hierarchical clustering was done on the 283 genes and 14 samples, with similarity metric set to uncentered correlation. Gene expression levels in the patients were compared prior to and after treatment by using the paired Student's t test, using P < 0.05 as significant. Statistical analyses were done with SPSS version 13.0 (SPSS Inc.).
Results
Twenty patients were enrolled in this study, of which 16 received seliciclib; 4 patients withdrew consent before receiving Stage*  IVB  IVB  IVB  IVB  III  III  IVB  III  IVB  III  IVB  III  IIA  III  T  3  2  4  1  2  2  4  3  2  1  2  3  2  2  N  3  3  3  3  2  2  3  2  3  2  3  2 (Table 1 ). All patients had localized disease with palpable cervical lymph nodes and were awaiting initiation of definitive treatment with radiotherapy or concurrent chemoradiation. Toxicity and tumor response. At dose level 1 dose (n = 3), only one patient completed treatment. One patient developed grade 2 nausea/vomiting after the first dose, and the second patient had grade 3 elevation of alanine aminotransferase and cholestatic jaundice on day 8. Hepatitis B and C serologies were negative in this patient. Both patients stopped therapy after the first week. At dose level 2 (n = 13), no side effect, in particular no significant elevation in creatinine or serum transaminases, was observed. Of the 14 evaluable patients, 7 (all on level 2) had >25% reduction in palpable cervical lymph nodes. Corresponding computed tomography scan assessments showed reductions in lymph nodes in the same patients ranging from 5% to 25% (Table 1 ). All patients had stable disease according to the Response Evaluation Criteria In Solid Tumors for response. Clear reduction in the nasopharyngeal tumor was seen on endoscopy in a patient (Fig. 1) . Radiographic evidence of necrosis in the cervical lymph nodes was seen after treatment in an additional two patients at dose level 2.
Serum pharmacokinetics. At the 800-mg bd dose level (n = 3), mean peak plasma concentration of seliciclib reached 6.6 F 1.5 Ag/mL at mean Tmax of 1.3 F 0.6 hours, resulting in a mean AUC 0-last of 22.8 F 9.6 Ag Â h/mL on day 1 (Fig. 2 ). The mean peak plasma level and AUC 0-last at the 400 mg bd dose (n = 13) was 5-fold lower at 1.3 F 0.7 Ag/mL, and 4.5 F 2.7 Ag Â h/mL, respectively. Both AUC 0-1 (n = 12) and Cmax (n = 13) on days 1 and 12 were similar for both doses.
Pharmacodynamic analysis. One patient at the 800-mg dose level and 13 patients at the 400-mg dose level had paired biopsy samples. The other two patients at the 800-mg dose level did not undergo pharmacodynamic analysis because they stopped dosing in the first week from toxicity.
Immunohistochemistry and histologic examination. Stored tumor samples from the initial patients were found to contain RNA preserving solution, and despite efforts to do antigen retrieval did not yield consistent results; therefore, six paired samples were finally analyzed and results agreed upon by two independent pathologists (Table 2 and Fig. 3) . Expression of Mcl-1 and cyclin D1 were clearly decreased posttreatment in three cases, phosphorylated retinoblastoma (pT821) expression was decreased in two samples, whereas Ser 807/811 was unchanged, indicating preferential cdk2 inhibition. Increased apoptosis as measured by TUNEL staining was seen in three patient samples. Ki-67 was decreased in only one patient. The percentage of necrotic area in relation to the overall sample area was calculated; only those cases with a clear, unequivocal difference were considered to have increased necrosis. Six of thirteen suitable paired specimens showed increased necrosis posttreatment ( Table 1) .
Effect of seliciclib on transcription. Fourteen tumor pairs yielded sufficient RNA and were adequate for analysis of gene expression, all of which contained z80% tumor on light microscopy. Unsupervised clustering analysis of all 380 genes showed two clear patient clusters with differential downregulation of genes (Fig. 4) . Greater than 25% of genes showed down-regulation of expression by >25% in the nine patients (5, 7, 8, 9, 14, 16, 17, 18, and 19) in one cluster. Comparison of this cluster of patients with clinical response showed close concordance; therefore this cluster was classified as responders whereas the cluster of five patients whose tumors did not show this pattern of transcriptional repression were classified as nonresponders. To generate hypotheses regarding the cellular effects of seliciclib exposure, we analyzed the responders for genes that were down-regulated to the greatest extent. This would then yield a panel of most significantly modulated genes at the transcriptional level that could be evaluated against the known cell cycle modulatory effects of seliciclib.
First, the mean gene expression level for all genes of pretreatment and posttreatment samples were compared in the nine responders, and 136 genes were found to be down-regulated posttreatment at P < 0.05 using paired t test. Using the GeneCards integrated database (www.genecards.org) and pathway analysis via the KEGG pathway database (www. genome.jp/kegg/pathway.html), 18 of 136 genes were antiapoptotic, 63 were involved in signal transduction, 41 were involved in the mitogen activated protein kinase (MAPK) pathway, 18 were related to cell proliferation and metabolism, 19 were implicated in RNA synthesis/DNA replication, and 10 were associated with DNA repair. Sixty-three genes represented those with the most significant transcriptional down-regulation (P < 0.02), of which the majority could be grouped into pathways involving four major signal transduction pathways: the MAPKs, including extracellular signal-regulated kinase (ERK), p38, and c-Jun NH 2 -terminal kinase (JNK); the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway; the nuclear factor nB (NFnB) pathway; and the phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) pathway (Table 3 ). In addition, genes pertinent to cellular proliferation like heat shock protein 70 (HSPA8), involved in folding of signal transduction proteins, protein phosphatase 1 (pNUTS), and general transcription factors (GTF3C4), DNA repair (ERCC4 and ERCC6, XPC), as well as transcription and translation initiation (eIF2A) were among the most significantly down-regulated genes (Table 3) . Taken together, this shows that seliciclib down-regulates genes that are important for promotion of tumor growth and cell survival in nasopharyngeal carcinoma.
Plasma EBV viral DNA load. Plasma EBV copy number, a marker of disease burden in nasopharyngeal carcinoma, was reduced by =25% in 4 of 13 patients after this brief exposure to seliciclib. 
Discussion
As development of cytostatic therapeutic agents with specific cellular targets progresses, it is crucial to understand the pharmacodynamic effects of these agents in tumor tissue to guide clinical development. Seliciclib is in phase II clinical trials in combination with chemotherapy; however, its cell cycle inhibitory effects in solid tumor have not previously been shown in patients. Therefore, this study provides the first evidence that seliciclib in clinically tolerable doses exerts effects in tumor cells consistent with cell cycle inhibition, and justifies its clinical development as an anticancer agent in particular in nasopharyngeal carcinoma, in which cell cycle dysregulation such as loss of p16
INK4a and overexpression of cyclin D1 could be targeted by cdk inhibition.
In this study, the higher dose of 800 mg bd achieved plasma concentrations that seemed to be higher than previously reported; it was tolerated poorly in the three patients treated, and one patient experienced grade 3 liver toxicity which is a known dose-limiting toxicity of seliciclib, whereas another patient developed grade 2 nausea/vomiting despite optimal antiemetics and diaphoresis. Dose reduction to 400 mg bd was feasible, with no major adverse events. However, the plasma concentrations at this dose resulted in a 5-fold drop in drug exposure. Despite this, antitumor effects were seen as evidenced by lymph node shrinkage after 2 weeks on clinical measurement and computed tomography scans, tumor necrosis/ apoptosis on light microscopy, and reduction in plasma EBV DNA in 4 of 13 patients by z25%, a validated marker of tumor burden in nasopharyngeal carcinoma. Immunohistochemistry of paired samples showed reduced phosphorylated retinoblastoma using a cdk2-but not cdk4-specific antibody, and reduced expression of cyclin D1 as well as Mcl-1, which are known effects of cell cycle inhibition by seliciclib in myeloma cell lines, B-cell chronic lymphocytic leukemia (5, 18) . Increase in the plasma EBV DNA after treatment occurred in 6 of 13 patients (from 19% to 279%). The discordance between the EBV viral DNA load and clinical responses could be due to the short 2-week interval between sampling points before and after treatment or assay variability. As plasma EBV viral DNA is mainly derived from tumor, it is possible that tumor apoptosis may result in initial increase in the plasma copy number.
To further elucidate the in vivo effects of seliciclib on oncogenic pathways pertinent to nasopharyngeal carcinoma, a panel of genes including those related to apoptosis, cell cycle, cell proliferation, DNA repair, and signal transduction was assessed using quantitative reverse transcription-PCR. Global down-regulation of transcription was observed in most patients studied. The pattern of genes significantly downregulated were consistent with those previously described in B chronic lymphocytic leukemia cells in vitro, including signal transduction, antiapoptotic, cell cycle, DNA repair, and cell proliferation genes. Specifically, antiapoptotic genes like TRAF5, BCL-2, and SIRT2 were down-regulated (18) . Similarly, down-regulation of DNA repair genes like XPA, ERCC4, and ERCC6 may impair cell survival to DNA damaging agents, and may suggest a possible role in combination with DNA damaging agents like cisplatin, an effective agent in treating nasopharyngeal carcinoma.
Of interest, the most significantly down-regulated genes were members of pathways that are known to be activated by latent membrane protein 1 (LMP1), an EBV-encoded gene that is known to mediate oncogenic properties by acting as a constitutively active tumor necrosis factor receptor. LMP1 is known to be expressed in the majority of nasopharyngeal carcinoma cells and is believed to contribute to EBV-mediated tumorigenesis and control of apoptosis through activation of signaling pathways that include the MAPK, JNK, p38, JAK/ STAT, NFnB, PI3K/AKT, and RhoGTPases (19, 20) . Seliciclib seems to have prominent down-regulatory effect on all these pathways, which may contribute to its positive clinical effects observed in this study. Other down-regulated genes of note were involved in initiation of transcription and translation including GTF3C4 and GTF2B/TFIIB, which may further impair transcription globally, collaborating with other effects to induce tumor cell apoptosis. Phosphatase 1 nuclear targeting subunit (pNUTS), a modulator of protein phosphatase 1 that regulates biological pathways like cell proliferation, differentiation, was significantly down-regulated in both cell lines as well as in the patient samples, and may be a critical target in seliciclibmediated cell cycle inhibition (21) .
Taken together, clinical doses of seliciclib can induce conditions that promote apoptosis in nasopharyngeal carcinoma through global transcriptional down-regulation, specifically genes mediating signal transduction via LMP1 signaling, which is consistent with its ability to inhibit cdk2, 7 and 9, and is in agreement with previously reported findings on chronic lymphocytic leukemia (18) .
Interestingly, these molecular perturbations, histologic changes, and clinical responses were seen at the 400-mg bd dose of seliciclib, which did not achieve plasma concentrations relevant to induce apoptosis in cell lines (IC 50 15 Amol/L) although high enough to be relevant for inhibition of CDK2, 7, and 9. It is well established that p-53 is wild-type in tumors from nasopharyngeal carcinoma patients (22 -24) . In vitro, seliciclib is known to be more potent against p-53 wild-type compared with p-53 mutant cell lines (6) . In support of this, we have found that in nasopharyngeal carcinoma cell lines, p-53 Table 3 . List of genes most significantly down-regulated after seliciclib treatment (P < 0.02) (26, 27) . Furthermore, colon and prostate cell lines with deleted or mutated p53 exhibit decreased sensitivity to apoptosis following RNA polymerase II inhibition (6, 28) . In summary, seliciclib is active in inducing cellular responses in nasopharyngeal carcinoma in vivo consistent with cell cycle inhibition at a dose of 400 mg bd, and supports further clinical development of this agent in nasopharyngeal carcinoma, both as a single agent and possibly in combination with cytotoxic agents like cisplatin. Together with the observed cellular effects consistent with known mechanisms of seliciclib, these findings form the basis of an efficacy study of single agent seliciclib in nasopharyngeal carcinoma, which is currently ongoing.
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